Drug Profile
Befovacimab - Bayer HealthCare
Alternative Names: Anti-TFPI antibody; BAY-109; BAY-1093884Latest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator Bayer HealthCare
- Class Antihaemorrhagics; Monoclonal antibodies
- Mechanism of Action Lipoprotein-associated coagulation inhibitor inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Haemophilia
Most Recent Events
- 28 Jun 2021 No recent reports of development identified for phase-I development in Haemophilia(Treatment-experienced) in Israel (IV)
- 28 Nov 2020 No recent reports of development identified for phase-I development in Haemophilia in Bulgaria (IV)
- 28 Nov 2020 No recent reports of development identified for phase-I development in Haemophilia in Germany (IV)